Missed abortion Medical Services in China

Missed abortion, also known as silent or delayed miscarriage, is a type of early pregnancy loss in which the embryo or fetus has died but remains retained within the uterine cavity without spontaneous expulsion. Unlike inevitable or incomplete abortions, missed abortion typically presents with absent or diminishing pregnancy symptoms—such as nausea, breast tenderness, and fatigue—without vaginal bleeding or cramping, making clinical detection challenging without ultrasound confirmation. Diagnosis requires transvaginal ultrasound demonstrating absence of fetal cardiac activity in a gestational sac measuring ≥25 mm (or ≥16 mm without yolk sac) or an embryo ≥7 mm without detectable heartbeat. Pathogenesis involves chromosomal abnormalities in over 50–70% of cases, most commonly autosomal trisomies (e.g., trisomy 16, 22), monosomy X, or triploidy. Other contributing mechanisms include maternal endocrine disorders (e.g., uncontrolled hypothyroidism, luteal phase defect), thrombophilias (e.g., antiphospholipid syndrome), immunologic dysregulation, chronic endometritis, and structural uterine anomalies (e.g., septate uterus). Environmental and lifestyle factors—including advanced maternal age (>35 years), smoking, excessive caffeine intake, obesity (BMI ≥30), prior recurrent pregnancy loss, and certain infections (e.g., parvovirus B19, listeriosis)—also elevate risk. Epidemiologically, missed abortion accounts for approximately 15–20% of all clinically recognized pregnancies and represents the most common subtype among first-trimester losses. Its incidence rises significantly with maternal age: ~10% in women aged 20–29, ~20% at age 35–39, and up to 40–50% beyond age 40. Psychologically, missed abortion profoundly impacts quality of life—triggering acute grief, anxiety, depression, and feelings of guilt or failure; many patients report prolonged emotional distress, disrupted partner relationships, and diminished sexual well-being. Delayed diagnosis may further exacerbate psychological burden due to uncertainty and perceived loss of control. Physical recovery is generally rapid post-treatment, but recurrent missed abortion warrants comprehensive reproductive immunology and genetic evaluation. Timely, empathetic counseling and multidisciplinary support—including reproductive endocrinology, psychology, and nursing—are essential components of holistic care in reproductive medicine departments.

Missed abortion—defined as the intrauterine demise of an embryo or fetus without spontaneous expulsion or clinical symptoms such as bleeding or cramping—is a distinct subtype of early pregnancy loss occurring typically before 20 weeks’ gestation, most commonly between 6–12 weeks. Unlike inevitable or incomplete abortions, missed abortion is characterized by a silent cessation of embryonic/fetal development, often detected incidentally during routine ultrasound when fetal cardiac activity is absent despite a gestational sac of appropriate size. The pathophysiology is multifactorial, involving complex interactions among genetic, endocrine, immunologic, thrombophilic, anatomical, infectious, and environmental determinants.

Genetic factors represent the single most prevalent cause, accounting for approximately 50–70% of missed abortions in the first trimester. Chromosomal abnormalities—predominantly aneuploidies including trisomies (e.g., trisomy 16, 21, 22), monosomy X (45,X), triploidy, and tetraploidy—are frequently identified in products of conception. These errors arise de novo during gametogenesis or early embryonic mitosis and are rarely inherited; advanced maternal age (>35 years) significantly increases risk due to declining oocyte quality and meiotic spindle integrity. Paternal factors—including sperm DNA fragmentation and certain karyotypic anomalies—may also contribute, though their independent contribution remains less well quantified.

Endocrine disturbances constitute another major category. Luteal phase deficiency—characterized by inadequate progesterone synthesis or impaired endometrial response—compromises decidualization and placental development. Uncontrolled thyroid dysfunction (especially subclinical or overt hypothyroidism with elevated TSH and/or positive thyroid peroxidase antibodies), poorly managed diabetes mellitus (HbA1c >6.5%), and hyperprolactinemia disrupt trophoblast invasion and vascular remodeling. Polycystic ovary syndrome (PCOS) confers elevated risk not solely via hyperandrogenism or insulin resistance but also through associated chronic low-grade inflammation and altered endometrial receptivity.

Anatomical factors include congenital uterine anomalies (e.g., septate uterus), intrauterine adhesions (Asherman syndrome), and significant leiomyomas—particularly submucosal or large intramural fibroids—that distort the endometrial cavity or impair placental implantation. Cervical insufficiency is less commonly implicated in missed abortion than in second-trimester losses but may coexist in women with prior trauma or surgical history.

Thrombophilic and immunologic mechanisms are increasingly recognized. Inherited thrombophilias—including factor V Leiden mutation, prothrombin G20210A variant, and protein C/S or antithrombin III deficiencies—predispose to placental microthrombosis and infarction. Antiphospholipid syndrome (APS), defined by persistent medium-to-high titer lupus anticoagulant, anticardiolipin IgG/IgM, or anti-β2-glycoprotein I antibodies, induces complement-mediated trophoblast injury and defective spiral artery transformation. Other autoimmune conditions (e.g., systemic lupus erythematosus, celiac disease) correlate with increased risk, likely via shared inflammatory pathways.

Environmental and lifestyle-related risk factors are modifiable yet clinically significant. Maternal smoking (>10 cigarettes/day) elevates carbon monoxide and nicotine exposure, inducing placental hypoxia and oxidative stress. Heavy alcohol consumption (>3 standard drinks/week) and illicit drug use (e.g., cocaine, methamphetamine) impair trophoblast proliferation and angiogenesis. Obesity (BMI ≥30 kg/m²) promotes chronic inflammation, dysregulated adipokine secretion, and endoplasmic reticulum stress in trophoblasts. Occupational exposures—including organic solvents (e.g., benzene, toluene), pesticides, ionizing radiation, and heavy metals (lead, mercury)—are associated with dose-dependent increases in embryonic lethality. Psychosocial stress, while difficult to quantify objectively, may influence hypothalamic-pituitary-adrenal axis modulation and uterine blood flow, though evidence remains associative rather than causal.

Infectious agents play a relatively minor role in isolated missed abortion but should be considered in endemic settings or with suggestive clinical features: Toxoplasma gondii, Listeria monocytogenes, parvovirus B19, and cytomegalovirus have all been linked to nonimmune hydrops and fetal demise. However, routine screening is not recommended in asymptomatic cases without epidemiologic risk.

Advanced maternal age (>35 years), prior recurrent pregnancy loss (≥2 consecutive losses), and a history of assisted reproductive technology (ART) cycles—particularly those involving blastocyst transfer or preimplantation genetic testing—also confer elevated risk, reflecting underlying oocyte quality issues or selection bias. Importantly, in up to 30–40% of cases, no definitive etiology is identified despite comprehensive evaluation, underscoring the biological complexity of early embryonic viability.

Missed abortion, also termed silent or delayed miscarriage, refers to the intrauterine demise of an embryo or fetus without spontaneous expulsion of pregnancy tissue. It is a subtype of early pregnancy loss occurring before 20 weeks’ gestation—most commonly between 6 and 12 weeks—and is characterized by the absence of overt clinical signs of miscarriage despite embryonic or fetal death confirmed by ultrasound. Unlike inevitable or incomplete abortion, missed abortion lacks active uterine contractions, cervical dilation, or vaginal bleeding in the initial phase, rendering it clinically silent and often detected only during routine prenatal evaluation.

Early symptoms are typically absent or nonspecific. Many patients remain asymptomatic, with continued perception of pregnancy—such as persistent breast tenderness, nausea, or fatigue—due to sustained placental hormone production (notably progesterone and human chorionic gonadotropin [hCG]) following embryonic demise. In some cases, women may report subtle regression of early pregnancy symptoms: diminished nausea, reduced breast fullness, or decreased urinary frequency. However, these changes are subjective, inconsistent, and not diagnostic; they frequently go unnoticed or are attributed to normal fluctuations in early gestation. Importantly, the persistence of positive urine or serum hCG tests does not exclude missed abortion, as trophoblastic tissue may remain viable and hormonally active for days to weeks after embryonic death.

Typical symptoms emerge later, often only after tissue degeneration or secondary complications develop. The most common presenting symptom is vaginal spotting or light brownish discharge—distinct from the bright red, heavy bleeding seen in incomplete abortion. This discharge reflects chronic decidual breakdown rather than acute uterine evacuation. Some patients experience mild, intermittent lower abdominal discomfort or dull pelvic pressure, but severe cramping is atypical. A critical clinical clue is the cessation of fetal movement in second-trimester missed abortions (though rare in this context, as most missed abortions occur earlier); however, fetal movement is not perceptible before 18–20 weeks, limiting its utility. Uterine size discrepancy—where fundal height fails to progress or regresses on serial examination—is a key physical finding, though it requires prior baseline assessment and is less reliable in obese or multiparous individuals.

Accompanying symptoms may include systemic manifestations related to coagulopathy or infection. In prolonged cases (>4 weeks), consumptive coagulopathy (e.g., disseminated intravascular coagulation [DIC]) may manifest as easy bruising, petechiae, mucosal bleeding, or prolonged bleeding after venipuncture. Fever, chills, foul-smelling vaginal discharge, uterine tenderness, or tachycardia suggest superimposed intrauterine infection (septic abortion), a serious complication requiring urgent intervention. Rarely, patients report malaise, low-grade fever, or vague constitutional symptoms preceding overt signs of sepsis.

Complications of missed abortion arise primarily from retained nonviable tissue. The most significant is DIC, triggered by thromboplastin release from degenerating placental villi, leading to hypofibrinogenemia, prolonged prothrombin time (PT)/activated partial thromboplastin time (aPTT), thrombocytopenia, and potentially life-threatening hemorrhage. Other complications include endometritis or parametritis, especially if tissue retention exceeds 3–4 weeks; Asherman syndrome (intrauterine adhesions) following aggressive curettage; and psychological sequelae such as acute grief, anxiety, or depression—warranting psychosocial support. Delayed management increases risks of infection, hemorrhage, and need for surgical intervention.

Diagnosis relies on a combination of clinical assessment and definitive imaging. Transvaginal ultrasound is the gold standard: diagnostic criteria include absence of embryonic cardiac activity in an embryo ≥7 mm crown-rump length (CRL); absence of a yolk sac in a gestational sac ≥25 mm mean sac diameter (MSD); or absence of an embryo with cardiac activity ≥2 weeks after a prior scan confirming a viable pregnancy. Serial quantitative serum β-hCG measurements may support diagnosis when levels plateau or decline abnormally slowly (e.g., <50% drop over 48 hours), though hCG kinetics alone are insufficient due to wide interindividual variability. Physical examination may reveal a closed cervix, uterine size smaller than expected for gestational age, and absence of fetal heart tones via Doppler. Laboratory evaluation includes complete blood count (CBC), coagulation profile (fibrinogen, PT/aPTT, D-dimer), and blood type/Rh status. Endometrial biopsy is obsolete and not recommended.

Differential diagnosis must exclude other causes of pregnancy failure or ultrasound discrepancies. Threatened abortion presents with vaginal bleeding and/or cramping but with a viable embryo and closed cervix—distinguishing feature is preserved cardiac activity. Inevitable abortion shows cervical dilation and active bleeding with confirmed nonviability, whereas missed abortion features a closed cervix and no active expulsion. Blighted ovum (anembryonic gestation) is a specific etiology of missed abortion but represents a distinct sonographic diagnosis: a gestational sac without an embryo, often with a yolk sac, and no subsequent development. Ectopic pregnancy must be ruled out in any woman with positive hCG and no intrauterine pregnancy on ultrasound—especially if adnexal mass, free fluid, or rising hCG without corresponding sac growth is present. Molar pregnancy may mimic missed abortion with elevated hCG and absent embryo but demonstrates characteristic vesicular trophoblastic tissue, markedly elevated hCG, and often uterine enlargement disproportionate to dates. Finally, technical factors—including operator-dependent ultrasound limitations, early gestational age (<5 weeks), or maternal obesity—can lead to false-negative viability assessment; thus, a follow-up scan in 7–10 days is indicated if viability cannot be confirmed and clinical suspicion remains high. Accurate diagnosis prevents unnecessary interventions and guides timely, evidence-based management—whether expectant, medical (misoprostol ± mifepristone), or surgical (vacuum aspiration)—while mitigating physical and emotional morbidity.

Missed abortion—also termed silent or delayed miscarriage—is a pregnancy complication in which embryonic or fetal demise occurs without spontaneous expulsion of gestational tissue. Diagnosis is confirmed via transvaginal ultrasound demonstrating absence of fetal cardiac activity in a gestation beyond the expected crown-rump length (CRL) threshold (typically ≥7 mm with no heartbeat) or an empty gestational sac ≥25 mm in mean sac diameter without a yolk sac or embryo. Patients are often asymptomatic, though some report diminished pregnancy symptoms, mild cramping, or brownish vaginal discharge. Management must be individualized based on gestational age, maternal hemodynamic stability, infection risk, Rh status, psychological readiness, and patient preference. Three primary modalities exist: conservative (expectant) management, medical management, and surgical evacuation.

Conservative (expectant) management involves close clinical observation without intervention, allowing for spontaneous passage of products of conception. This approach is appropriate for hemodynamically stable patients with no signs of infection, coagulopathy, or significant hemorrhage, typically within the first trimester (≤13 weeks’ gestation). Success rates range from 65% to 80% within 2–4 weeks; however, unpredictability of timing, risk of incomplete expulsion, prolonged bleeding (>2 weeks), and potential need for unplanned surgical intervention limit its utility. Serial beta-hCG monitoring and repeat ultrasound at 1–2 weeks are mandatory to confirm complete resolution. Counseling must emphasize warning signs—including fever >38°C, heavy bleeding (>2 soaked pads/hour), severe pain, or foul-smelling discharge—requiring urgent evaluation.

Medical management employs pharmacologic agents to induce uterine contractions and cervical ripening. The gold-standard regimen combines mifepristone (200 mg orally, single dose) followed 24–48 hours later by misoprostol (800 mcg vaginally or 600 mcg sublingually). Mifepristone blocks progesterone receptors, sensitizing the myometrium and softening the cervix; misoprostol—a prostaglandin E1 analog—induces coordinated uterine contractions. Complete expulsion occurs in 85–95% of cases within 7 days. Alternatives include misoprostol monotherapy (600–800 mcg vaginally), though efficacy is lower (~75%) and side effects (diarrhea, chills, nausea) more frequent. Contraindications include allergy to prostaglandins, chronic adrenal failure, concurrent anticoagulant use, or suspected ectopic pregnancy. Rh-negative patients require anti-Rh(D) immunoglobulin post-treatment. Medical management offers high efficacy, avoids anesthesia and instrumentation, preserves cervical integrity, and supports patient autonomy—yet requires reliable follow-up and access to emergency care.

Surgical treatment—primarily vacuum aspiration (VA) under local or conscious sedation—is indicated for hemodynamic instability, active heavy bleeding, suspected infection (e.g., endometritis), failed medical/conservative management, gestational age >13 weeks, or patient preference for definitive, time-limited resolution. Manual vacuum aspiration (MVA) or electric vacuum aspiration (EVA) achieves >99% success with minimal uterine trauma when performed by trained reproductive medicine specialists. Complication rates are low (<2%): uterine perforation (0.1%), cervical laceration (0.2%), intrauterine adhesions (Asherman syndrome, <0.5%), and infection (<1%). Preoperative antibiotics (e.g., doxycycline 200 mg orally) reduce infectious morbidity. Ultrasound-guided procedures enhance safety and completeness, particularly in early or anatomically complex cases. Surgical management provides rapid symptom resolution, immediate histopathologic confirmation of pregnancy tissue, and psychological closure for many patients.

China’s reproductive medicine centers offer distinct advantages in missed abortion care. First, standardized national clinical pathways—endorsed by the Chinese Medical Association’s Reproductive Medicine Branch—ensure evidence-based, protocol-driven decision-making across tertiary hospitals. Second, widespread integration of point-of-care ultrasound enables real-time assessment and procedural guidance, minimizing diagnostic delay. Third, China leads globally in the development and regulatory approval of domestically manufactured, high-purity misoprostol and mifepristone formulations with stringent batch consistency, ensuring therapeutic reliability. Fourth, multidisciplinary support—including dedicated reproductive psychology services, fertility preservation counseling, and preconception genetic screening programs—is routinely embedded within reproductive medicine departments. Fifth, cost-effectiveness is notable: outpatient medical management and same-day surgical evacuation are widely accessible under basic medical insurance, with out-of-pocket expenses averaging <USD 150 for pharmacologic regimens and <USD 300 for ultrasound-guided VA. Finally, robust digital health infrastructure allows seamless longitudinal tracking of beta-hCG trends, menstrual recovery, and subsequent fertility outcomes via integrated hospital EMR systems.

Post-procedure recovery emphasizes both physiological and psychosocial healing. Patients should abstain from sexual intercourse, tampon use, douching, and swimming for ≥2 weeks to prevent infection. Mild cramping and intermittent spotting (≤14 days) are expected; persistent bright-red bleeding beyond 10 days, clots >2.5 cm, or fever warrants re-evaluation. Iron supplementation (ferrous sulfate 325 mg daily) is recommended for those with hemoglobin <12 g/dL or prolonged bleeding. Menstruation typically resumes within 4–6 weeks; ovulation may occur as early as 2 weeks post-evacuation, necessitating contraception counseling. Psychological support is critical: up to 40% of patients experience acute grief, anxiety, or depression; referral to certified reproductive mental health specialists is standard practice in leading Chinese centers. Preconception evaluation—including thyroid function, HbA1c, rubella immunity, and karyotyping (if recurrent loss) —is advised after two consecutive normal cycles. Most patients achieve successful subsequent pregnancy within 6–12 months; cumulative live birth rates exceed 85% in the absence of underlying structural or thrombophilic disorders. Long-term follow-up includes endometrial assessment if amenorrhea persists beyond 8 weeks or if conception fails after 12 months of unprotected intercourse.